In a filing, Cytokinetics Inc revealed its President & CEO Blum Robert I unloaded Company’s shares for reported $0.25 million on Dec 02 ’24. In the deal valued at $50.76 per share,5,000 shares were sold. As a result of this transaction, Blum Robert I now holds 397,678 shares worth roughly $20.13 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ROBERT BLUM bought 5,000 shares, generating $253,786 in total proceeds.
Before that, Malik Fady Ibraham sold 7,300 shares. Cytokinetics Inc shares valued at $366,181 were divested by the EVP Research & Development at a price of $50.16 per share. As a result of the transaction, Malik Fady Ibraham now holds 111,878 shares, worth roughly $5.66 million.
RBC Capital Mkts initiated its Cytokinetics Inc [CYTK] rating to an Outperform in a research note published on November 08, 2024; the price target was $80. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. UBS also remained covering CYTK and has decreased its forecast on January 24, 2024 with a “Neutral” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 05, 2024. It rated CYTK as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -2.37% to $50.63. Over the last five days, the stock has gained 3.12%. Cytokinetics Inc shares have fallen nearly -39.36% since the year began. Nevertheless, the stocks have risen 51.22% over the past one year. While a 52-week high of $110.25 was reached on 01/08/24, a 52-week low of $32.35 was recorded on 05/28/24. SMA at 50 days reached $53.17, while 200 days put it at $58.73.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 50.06, which if violated will result in even more drops to 49.48. On the upside, there is a resistance level at 51.43. A further resistance level may holdings at 52.22. The Relative Strength Index (RSI) on the 14-day chart is 44.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.10%. Stochastics %K at 35.07% indicates the stock is a holding.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2024-11-15, dropping by -0.95 million shares to a total of 14.59 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 15.54 million shares. There was a decline of -6.51%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 09, 2023 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
